CELH
Celsius Holdings, Inc.
CELH has the edge over MDLZ overall, supported by stronger fundamentals and stronger valuation.
MDLZ
Mondelez International, Inc.
MDLZ has lower modeled downside risk, despite its lower overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MDLZ Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
MDLZ's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
MDLZ PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 20x | $64.07 | -3.7% |
| Forward | 20x | $66.56 | — |
| Current | 21x | $66.56 | — |
| Fair | 22x | $71.08 | +6.8% |
| Expensive | 26x | $83.55 | +26% |
Historical ranges are pointers, not guarantees.
MDLZ has the edge over CELH in the historical PE scenario, which offers more potential upside but is not a forecast.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
CELH has the edge over MDLZ on the outlook, with more favorable valuation and revenue expectations.
MDLZ Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect MDLZ's earnings to grow and its profitability to improve, with its revenue holding steady.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
MDLZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.31 | +4.1% |
| Q3 2026 | $3.18 | +19% |
| Q2 2026 | $2.73 | 0% |
| Q1 2026 | $2.02 | -25% |
| Q4 2025 | $1.89 | -45% |
| Q3 2025 | $2.67 | -5% |
| Q2 2025 | $2.73 | -5.9% |
| Q1 2025 | $2.69 | -14% |
| Q4 2024 | $3.42 | -5.5% |
MDLZ earned $3.18 per share over the past year, up 19% from the year before.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH's revenue has grown year over year for six quarters in a row: $847M last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over MDLZ on profitability, with a higher operating margin.
MDLZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10B | +2.3% |
| Q2 2026 | $9.4B | +4.1% |
| Q1 2026 | $10.1B | +8.2% |
| Q4 2025 | $10.5B | +9.3% |
| Q3 2025 | $9.7B | +5.9% |
| Q2 2025 | $9B | +7.7% |
| Q1 2025 | $9.3B | +0.2% |
| Q4 2024 | $9.6B | +3.1% |
MDLZ's revenue has grown year over year for nine quarters in a row: $10B last quarter, up 2.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +10 points |
| Q2 2026 | 21% | +7.8 points |
| Q1 2026 | 8% | +0.7 points |
| Q4 2025 | 9.1% | -7.7 points |
| Q3 2025 | 7.6% | -4.9 points |
| Q2 2025 | 13% | +2.8 points |
| Q1 2025 | 7.3% | -22 points |
| Q4 2024 | 17% | +4 points |
MDLZ's operating margin was 18% last quarter, up 10 points from the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH has the edge over MDLZ on cash flow, with more consistent year-over-year improvement.
MDLZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $991M | +137% |
| Q2 2026 | $513M | +17000% |
| Q1 2026 | $155M | -81% |
| Q4 2025 | $2B | +90% |
| Q3 2025 | $418M | -58% |
| Q2 2025 | $3M | -99% |
| Q1 2025 | $815M | -20% |
| Q4 2024 | $1.1B | -14% |
MDLZ's free cash flow has been positive every quarter for seven years: $3.7B over the past year, up 60% from the year before.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has 255M diluted shares, down 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
MDLZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -7M shares |
| 1 year | -1.2% | -16M shares |
| 3 years | -6.6% | -90M shares |
| 5 years | -9.1% | -128M shares |
| Available history | -12% | -173M shares |
MDLZ has the edge over CELH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $633M |
| Q2 2026 | $212M |
| Q1 2026 | — |
| Q4 2025 | $492M |
| Q3 2025 | $240M |
| Q2 2025 | $131M |
| Q1 2025 | $1.5B |
| Q4 2024 | $1.1B |
MDLZ spent $1.3B buying back its own shares over the past year, down 56% from the year before.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over MDLZ on leverage, with a lower net debt burden relative to earnings.
MDLZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.9x | Moderate |
| Q2 2026 | 3.4x | Elevated |
| Q1 2026 | 3.8x | Elevated |
| Q4 2025 | 3.9x | Elevated |
| Q3 2025 | 3.6x | Elevated |
| Q2 2025 | 3.3x | Elevated |
| Q1 2025 | 3.2x | Elevated |
| Q4 2024 | 2.1x | Moderate |
MDLZ's net debt is about 2.9 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
MDLZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.7 | Neutral |
| Stochastic | 79.5 | Neutral |
MDLZ's weekly RSI is 63 (neutral) and its Stochastic is 80 (neutral).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
MDLZ PE vs Consumer Defensive Sector
| Metric | MDLZ | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 19x | 7.4% above |
| PE % | 28 | 18 | 10 pts above |
MDLZ has the edge over CELH on valuation relative to its sector.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
MDLZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.0 | 5.6% above |
| 20 week MA | $62.3 | 6.9% above |
| 50 week MA | $60.0 | 11% above |
| 100 week MA | $61.6 | 8% above |
| 200 week MA | $65.9 | 1.1% above |
MDLZ has the edge over CELH on trend strength, trading above more of its moving averages.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
MDLZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $55.3 | $57.9 | +4.6% |
| 2021 | $57.9 | $64.9 | +12% |
| 2022 | $64.9 | $67.1 | +3.3% |
| 2023 | $67.1 | $72.4 | +7.9% |
| 2024 | $72.4 | $60.2 | -17% |
| 2025 | $60.2 | $54.6 | -9.3% |
| 2026 YTD | $54.6 | $66.6 | +22% |
MDLZ has the edge over CELH on returns for 2026, with the stronger performance.